OAB
Astellas’ application to EMA validated for treatment of muscle-invasive bladder cancer
Bladder cancer affects over 224,000 people annually in Europe, with over 30% of cases being muscle-invasive bladder cancer
Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment
Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
About 614,000 people are diagnosed with bladder cancer globally every year
Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn
Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder
Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment
Approximately 136,000 cases of the disease are diagnosed in Europe every year
Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval
Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases
Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer
Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe
Astellas announces EC approval of Xtandi for expanded prostate cancer use
Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years
Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m
As part of the deal, Xyphos will combine its iGPS system with Kelonia’s ACCEL technology
Astellas’ menopause drug granted EC approval to treat vasomotor symptoms
More than half of women aged 40 to 64 years experience symptoms such as hot flashes
Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
Vasomotor symptoms affect up to 80% of menopausal women in the US
Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication
Xtandi is the first androgen receptor signalling inhibitor approved for this patient population